UNSPSC 51272203: Esketamine

This classification denotes an anesthetic agent with the molecular formula C13H16ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50LFG02TXD, chemically known as cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8ci) but generally known as esketamine, which bears US NIH Compound Identifier 3821. European Medicines Agency schedules Esketamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25825.

UNSPSC 51272203 Esketamine is a Commodity-tier code that nominally designates a specific pharmaceutical product, but recent state and local procurement activity under this code shows minimal direct solicitation for esketamine itself. Instead, state and local issuers have tagged opportunities for broader pharmaceutical procurement, naloxone distribution, and pharmacy benefit program management under this code, suggesting either misclassification in the procurement systems or that this code is used as a catch-all for specialty and emergency-response pharmaceuticals. The issuing bodies engaging under the code include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across participating jurisdictions including Oregon). Work being solicited ranges from direct naloxone and drug deactivation system procurement to manufacturer direct-contracting arrangements for prescription fulfillment and generic pharmaceutical supply agreements through authorized wholesalers.

Geographic activity concentrates in Florida, Texas, Minnesota, and participating cooperative member states. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription program capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers, with awards effective July 1, 2026. Vendors must typically comply with cGMP certification, Drug Supply Chain Security Act requirements, E-Verify employment verification, and comprehensive insurance including commercial general liability coverage. The code shows fragmented issuing activity rather than sustained demand from a concentrated buyer base, and the mismatch between the esketamine commodity designation and the actual pharmaceutical procurement scope suggests caution in relying on code alignment for opportunity discovery.